Literature DB >> 33716832

The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia.

Xing-Jie Peng1,2,3,4, Gang-Rui Hei1,2,3,4, Ye Yang1,2,3,4, Chen-Chen Liu1,2,3,4, Jing-Mei Xiao1,2,3,4, Yu-Jun Long1,2,3,4, Jing Huang1,2,3,4, Jing-Ping Zhao1,2,3,4, Ren-Rong Wu1,2,3,4,5.   

Abstract

Background: Schizophrenia is a severe mental disease which characterized by positive symptom, negative symptom, general pathology syndrome and cognitive deficits. In recent years, many studies have investigated the relationship between cognitive deficits and clinical characteristics in schizophrenia, but relatively few studies have been performed on first-episode drug-naïve patients.
Methods: Eighty seven first-episode drug-naïve schizophrenia patients were assessed for positive symptom, negative symptom, general pathology symptom and cognitive deficits from the Positive and Negative Symptom Scale and MATRICS Consensus Cognitive Battery. Psychotics depression were assessed using the Calgary depressing scale for schizophrenia. The relationship between clinical characteristics and cognitive deficits were assessed using correlation analysis and linear regression analysis.
Results: The prevalence of cognitive deficits among the patients in our study was 85.1% (74/87) which was much higher than that in the general population. According to correlation analysis, negative symptom was negatively correlated with speed of processing and social cognition, and general pathology showed a negative correlation with attention/vigilance. In addition, a positive correlation was found between age and speed of processing. No correlation was found between cognitive deficits and positive symptom. Conclusions: This study confirmed that negative symptom is negatively related with some domains of cognitive function in first-episode drug naïve schizophrenia patients. Trail Registration: NCT03451734. Registered March 2, 2018 (retrospectively registered).
Copyright © 2021 Peng, Hei, Yang, Liu, Xiao, Long, Huang, Zhao and Wu.

Entities:  

Keywords:  MCCB; cognitive impairment; correlation analysis; first episode drug-naïve schizophrenia; positive and negative symptoms

Year:  2021        PMID: 33716832      PMCID: PMC7950319          DOI: 10.3389/fpsyt.2021.638773

Source DB:  PubMed          Journal:  Front Psychiatry        ISSN: 1664-0640            Impact factor:   4.157


  40 in total

1.  The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia.

Authors:  S R McGurk; P J Moriarty; P D Harvey; M Parrella; L White; K L Davis
Journal:  Schizophr Res       Date:  2000-03-16       Impact factor: 4.939

2.  Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection.

Authors:  Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-05       Impact factor: 2.475

3.  Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance.

Authors:  Sofia Brissos; Vasco Videira Dias; Vicent Balanzá-Martinez; Ana Isabel Carita; Maria Luísa Figueira
Journal:  Schizophr Res       Date:  2011-04-22       Impact factor: 4.939

4.  Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF.

Authors:  Xinyu Fang; Yan Chen; Yewei Wang; Juanjuan Ren; Chen Zhang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-06-24       Impact factor: 5.067

5.  Age or age at onset? Which of them really matters for neuro and social cognition in schizophrenia?

Authors:  Magdalena Linke; Konrad S Jankowski; Agnieszka Ciołkiewicz; Małgorzata Jędrasik-Styła; Dorota Parnowska; Anna Gruszka; Mirella Denisiuk; Marek Jarema; Adam Wichniak
Journal:  Psychiatry Res       Date:  2014-11-24       Impact factor: 3.222

Review 6.  Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients.

Authors:  G Cassens; A K Inglis; P S Appelbaum; T G Gutheil
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

7.  Schizophrenia is a cognitive illness: time for a change in focus.

Authors:  René S Kahn; Richard S E Keefe
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

8.  Cognitive functioning in the schizophrenia prodrome.

Authors:  Andor E Simon; Katja Cattapan-Ludewig; Solange Zmilacher; Dima Arbach; Kerstin Gruber; Diane N Dvorsky; Binia Roth; Emanuel Isler; Alexander Zimmer; Daniel Umbricht
Journal:  Schizophr Bull       Date:  2007-04-04       Impact factor: 9.306

9.  Schizophrenia-An Overview.

Authors:  Robert A McCutcheon; Tiago Reis Marques; Oliver D Howes
Journal:  JAMA Psychiatry       Date:  2020-02-01       Impact factor: 21.596

10.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Authors:  Richard S E Keefe; Robert M Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Journal:  Arch Gen Psychiatry       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.